Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

Pty Ltd
Level 9, 278 Collins Street, Melbourne, 3000, Australia
www.hatchtech.com.au

About DeOvo™Despite its prevalence and high cost to the community, there have been few major advances in controlling head lice infestation in recent years. Most pediculicide products have little ovicidal activity and require two treatments (approximately 7 days apart), with the second application designed to treat those lice which have hatched from eggs that survive the first treatment. Non-compliance with this regimen and the difficulty in choosing the optimal time for the second application, are major difficulties in using these products. Hatchtech's DeOvo™, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offers the potential for a more effective treatment following a single application.

About PediculosisIt is estimated that 6-12 million people, in the United States, mainly children aged 3-12, are infested each year with head lice (Pediculus humanus capitis). The direct cost of treatment is estimated at several hundreds of millions of dollars. Added to this direct economic burden are the indirect costs including missed days from school, lost work productivity by parents who stay home to treat their children and costs borne by the school itself in trying to control or prevent this problem. The total costs have been estimated to be 1billion USD in the US alone.


'/>"/>

SOURCE Hatchtech Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Depomed, Inc. (NASDAQ: ... at the 27 th Annual Roth Conference in ... for 12:30 pm ET (9:30 am PT) Tuesday, March 10, 2015. ... webcast can be accessed via the Investor Relations page of ... the webcast will be archived for 30 days on the ...
(Date:3/3/2015)... Denovo Biopharma, LLC, today announced that ... agonist), a late-stage neuroscience drug, from Eli Lilly ... rights to develop, manufacture and commercialize pomaglumetad globally, ... rights, data, and information. Lilly has an option ... for predetermined undisclosed financial terms.  ...
(Date:3/3/2015)... March 3, 2015  Blueprint Medicines today announced ... and commercialize novel drug candidates for an undisclosed ... a rare genetic disease. Blueprint Medicines will apply ... optimize drug candidates and will conduct all research ... New Drug (IND) application with the Food and ...
Breaking Medicine Technology:Depomed To Present At 27th Annual Roth Conference 2Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine 2Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease 2
... Medical Partners, the specialty pharmaceutical subsidiary of H. ... cold chain services agreement with Cardium Therapeutics (NYSE ... and regenerative medicine company, to support its recently ... professional-use, syringe-based wound care product used in the ...
... Care Corporation ("CompCare") (OTC BB: CHCR), a leading behavioral ... for managed care companies throughout the U.S., is pleased ... doubled to $71,210,000 compared to revenues of $35,214,000 in ... Chief Executive Officer said, "To continue our upward growth ...
Cached Medicine Technology:Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™ 2Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™ 3Comprehensive Care Corporation Doubles Its 2011 Revenues to Over $71 Million 2Comprehensive Care Corporation Doubles Its 2011 Revenues to Over $71 Million 3
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
(Date:3/3/2015)... March 03, 2015 Dallas plastic ... chairman of the upcoming Dallas Rhinoplasty Symposium, to be ... day symposium, which is attended by plastic surgeons and ... surgeons with detailed information on current topics, emerging techniques, ... rhinoplasty surgery . , The symposium will cover ...
(Date:3/3/2015)... San Jose, CA (PRWEB) March 03, 2015 ... cross-device computing and collaboration, announces Mirroring360 is now available ... Available for download from the Moverio Apps Market ... redirect their mobile device experience to the Epson Moverio ... empowering new usage models. , The Epson ...
(Date:3/3/2015)... 03, 2015 Birth Boot Camp ... they now have over 130 certified instructors in more ... Germany. In addition, the company recently launched a new ... childbirth educator certification program . Birth Boot Camp is ... birth partner. The practical information can be used by ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 OncLive® ... Center have joined forces to share news about ... today. The collaboration is part of OncLive’s Strategic ... alliance, OncLive’s editorial and marketing teams will partner ... Cancer Institute-designated cancer center, to highlight accomplishments. They ...
Breaking Medicine News(10 mins):Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 3Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 2Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 3Health News:Expectant Couples Worldwide Can Now Receive Training and Education in Natural Childbirth and Breastfeeding from Birth Boot Camp 2Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 2Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 3
... especially migraines, are more likely to be depressed,// feel ... symptoms, according to a study. ,The study involved ... the women surveyed, 593 reported episodic headache (fewer than ... (more than 15 headaches per month). Ninety percent of ...
... maximal therapy with minimal side effects - Scientists of ... School,// Greece, has been awarded a grant from the ... validation of new therapeutic strategies for cancer. ... activate a protein at the surface of ovarian, lung ...
... People suffering from muscular dystrophy should avoid over exercising, ... the arms or legs after exercise can be caused ... Germany Professional Association of Neurologists. ,Muscular dystrophy is ... over 30 forms of the condition have been identified. ...
... It sounds like something out of a very scary science ... tackled.// , A leading vet of Britain is ... the seasonal flu. ,Fred Landeg, deputy chief veterinary officer ... vets and farm workers before this year’s flu season. This ...
... cleft lip/palate faces predisposing factors to acquiring dental ... and provides strategies for early prevention. The study ... ,Cleft lip/palate is the most common congenital ... Patients with cleft conditions generally display poorer oral ...
... times are over for those who prefer relaxing with a ... study conducted by researchers from Charite Hospital Universitatsmedizin in Berlin, ... out with a study that shows adding milk to your ... ,Tea is known to contain flavonoids like catechins, ...
Cached Medicine News:Health News:Avian Nightmare 2
... (1.5x) Gonio lens will enable visualization of ... mirror lens is the industry preferred standard ... features : , Crispest, clearest imaging ... unattainable with Gonio lenses., 4 equally angled ...
... alternative to bulky biometry devices that have ... AP2000 is the world's only battery-operated, fully ... the market today. Each unit weighs a ... perform multiple functions, namely: auto data capture, ...
... The PiGalileo™ ... System from PLUS ... Surgery technology and ... technologies to assist ...
... a low TLR (<1%) and stroke rate ... and long-term durability., , , High Radial ... carotid artery, increasing lumen diameter with chronic ... Minimal stent shortening, low profile design, Cordis ...
Medicine Products: